Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Goldman Sachs upgraded BioNTech (BNTX) to Buy from Neutral with a price target of $137, up from $90. The firm upgrade the shares after ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Florida Gov. Ron DeSantis is advocating for President-elect Donald Trump to tap Florida Surgeon General Joseph Ladapo for the ...

Barnstable County Department of Health and Environment’s Public Health Nursing Division will conduct its second public COVID-19/flu clinic on Wednesday, November 20, from 10 AM to 1 PM in the ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

The UK is making progress in developing cancer vaccines, but there are still challenges ahead, Chris Baraniuk reports The UK is on its way to becoming a hotbed of cancer vaccine trials. In May this ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

How are the new vaccines different from last fall’s boosters? The updated mRNA vaccines from Moderna and Pfizer-BioNTech target the KP.2 strain, part of the Omicron lineage that began spreading last ...